Iterum Therapeutics plc (ITRM) stock was down -18.79% to $1.21 in the pre-market opening session.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Some of the most experienced traders have found the stock market to be extremely confusing, sometimes taking them completely by surprise. The market sometimes turns abruptly in the opposite direction, even when results are as projected. At times like this, it pays to keep tabs on a stock’s historical price performance. Knowledge of the short- and long-term stock trends would also be useful. The share prices of Iterum Therapeutics plc (NASDAQ: ITRM) have increased by 7.97% over the past week but are up 223.84% over prices last quarter. Over the last 6 months, the stock surged 40.57% and is up 50.66% for the year.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Latest Highlights
In response to demand, The Iterum Therapeutics plc (Nasdaq: ITRM) just revealed that, for a price of $1.15 per share, the underwriters have agreed to increase the size of the previously announced offering and purchase 34,782,609 ordinary shares (or warrants) at $1.15 per share. Moreover, the Company granted the underwriter an option to purchase 517,391 additional ordinary shares for the same price for another 30 days. This offering is expected to close between February 8, 2021, and March 8, 2021. The offering is subject to meeting the usual closing conditions.
HC Wainwright & Co. is acting as the sole bookrunner of the offering.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
After paying underwriting discounts and commissions and other offering expenses, the Company expects to reap approximately $40.0 million in gross proceeds. This will enable the Company to support ongoing review of its new drug application in patients with a drug-resistant, quinolone-susceptible pathogen, engage in pre-commercialization activities, and for working capital and general corporate purposes. With regards to the Company’s current operating plan, it estimates that after closing of the offering it will be able to fund its operating expenses and capital expenditures through the third quarter of 2022, including through the July 25, 2021 FDA review deadline for oral sulopenem. The company’s operating plans may change due to various factors and uncertainties, but this estimate is based on assumptions that may be wrong.